February 5, 2019

Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, NY 10020

       Re: Hoth Therapeutics, Inc.
           Amendments Nos. 3 and 4 to
           Registration Statement on Form S-1
           Filed February 1, 2019 and February 4, 2019
           File No. 333-227772

Dear Mr. Knie:

      We have reviewed your amended registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our February 1,
2019 letter.

Form S-1 Amendment No. 3 filed February 1, 2019

Exclusive Forum, page 82

1.     We note your response to prior comment 2. However, it is not clear
whether your
       exclusive forum provision applies solely to state law claims. Please
disclose whether this
       provision applies to actions arising under the Securities Act or
Exchange Act. If this
       provision does not apply to actions arising under the Securities Act or
Exchange Act,
       please also ensure that the exclusive forum provision in the governing
documents states
       this clearly. If the provision applies to Securities Act claims, please
revise your
       prospectus to disclose this information and to state that there is
uncertainty as to whether a
       court would enforce such provision, and to state that stockholders will
not be deemed to
 Robb Knie
Hoth Therapeutics, Inc.
February 5, 2019
Page 2
         have waived the company's compliance with the federal securities laws
and the rules and
         regulations thereunder.
       You may contact Effie Simpson at 202-551-3346 or Doug Jones at
202-551-3309 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Julie Griffith at 202-551-7574 or Susan Block at 202-551-3210 with any
other questions.



FirstName LastNameRobb Knie                                 Sincerely,
Comapany NameHoth Therapeutics, Inc.
                                                            Division of
Corporation Finance
February 5, 2019 Page 2                                     Office of
Transportation and Leisure
FirstName LastName